ORC ID , Farid V Bashirov1, Mikhail E Sokolov1, Andrei A Izmailov1, Filip O Fadeev1, Vage A Markosyan1, Maria A Davleeva1, Olga V Zubkova2, Maxim M Smarov2, Denis Yu Logunov2, Boris S Naroditskyi2, Ilnur I Salafutdinov3, Albert A Rizvanov PhD 3 ORC ID , Ramil G Turaev4">
  • Users Online: 6916
  • Home
  • Print this page
  • Email this page
RESEARCH ARTICLE
Year : 2021  |  Volume : 16  |  Issue : 2  |  Page : 357-361

Gene-modified leucoconcentrate for personalized ex vivo gene therapy in a mini pig model of moderate spinal cord injury


1 Kazan State Medical University, Kazan, Russia
2 Gamaleya Research Institute of Epidemiology and Microbiology, Moscow, Russia
3 Kazan Federal University, Kazan, Russia
4 The Republican Blood Center of the Ministry of Health of the Republic of Tatarstan, Kazan, Russia

Correspondence Address:
Albert A Rizvanov
Kazan Federal University, Kazan
Russia
Rustem R Islamov
Kazan State Medical University, Kazan
Russia
Login to access the Email id

Source of Support: This study was supported by the Russian Science Foundation (No. 16-15-00010; to RRI). AAR was supported by the Russian Government Program of Competitive Growth of Kazan Federal University, Conflict of Interest: None


DOI: 10.4103/1673-5374.290902

Rights and Permissions

We previously demonstrated that gene-modified umbilical cord blood mononuclear cells overexpressing a combination of recombinant neurotrophic factors are a promising therapeutic approach for cell-mediated gene therapy for neurodegenerative diseases, neurotrauma, and stroke. In this study, using a mini pig model of spinal cord injury, we proposed for the first time the use of gene-modified leucoconcentrate prepared from peripheral blood in the plastic blood bag for personalized ex vivo gene therapy. Leucoconcentrate obtained from mini pig peripheral blood was transduced with a chimeric adenoviral vector (Ad5/35F) that carried an enhanced green fluorescent protein (EGFP) reporter gene in the plastic blood bag. The day after blood donation, the mini pigs were subjected to moderate SCI and four hours post-surgery they were intravenously autoinfused with gene-modified leucoconcentrate. A week after gene-modified leucoconcentrate therapy, fluorescent microscopy revealed EGFP-expressing leucocytes in spinal cord at the site of contusion injury. In the spleen the groups of EGFP-positive cells located in the lymphoid follicles were observed. In vitro flow cytometry and fluorescent microscopy studies of the gene-modified leucoconcentrate samples also confirmed the production of EGFP by leucocytes. Thus, the efficacy of leucocytes transduction in the plastic blood bag and their migratory potential suggest their use for temporary production of recombinant biologically active molecules to correct certain pathological conditions. This paper presents a proof-of-concept of simple, safe and effective approach for personalized ex vivo gene therapy based on gene-modified leucoconcentrate autoinfusion. The animal protocols were approved by the Kazan State Medical University Animal Care and Use Committee (approval No. 5) on May 27, 2014.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed243    
    Printed1    
    Emailed0    
    PDF Downloaded77    
    Comments [Add]    

Recommend this journal